Eikon Therapeutics, Inc.EIKN
Oncology21 cited findings · profile updated 2026-08-20
12.01 USDnot live — refreshed daily
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. (EIKN) is an oncology research site. The company's pipeline includes EIK1003, which has been studied as monotherapy and in combination with paclitaxel. EIK1003 monotherapy demonstrated an Objective Response Rate (ORR) of 100% in Prostate Cancer and 0% in Pancreatic Cancer (Cohort 1A). In combination with paclitaxel, EIK1003 achieved a Disease control rate (DCR) of 79.2% (Cohort 1C).
Another key drug, EIK1001, is being investigated in the TeLuRide-005 trial, showing an Objective Response Rate (ORR) of 63.1% and a Disease Control Rate (DCR) of 90.8%. Within the TeLuRide-005 trial, the SQ cohort exhibited an ORR of 72.4% and a DCR of 100%. The NSQ cohort in the same trial had an ORR of 55.6% and a DCR of 83.3%, with a Median Duration of Response (DOR) of > 11 months.
Eikon Therapeutics also plans to initiate the TeLuRide-006 trial in Q2 2025. EIK1003 monotherapy in PARPi Naïve patients showed an ORR of 26.7% and a median duration of response (DOR) in confirmed responders of 7.8 months (Cohort 1A).
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Objective Response Rate (ORR) in Prostate Cancer | 100% | Eikon Therapeutics, Inc. — SEC 8-K (2026-08-14), p.5 |
| Disease control rate (DCR) with EIK1003 + paclitaxel | 79.2% | Eikon Therapeutics, Inc. — SEC 8-K (2026-08-14), p.6 |
| Objective Response Rate (ORR) for EIK1001 (TeLuRide-005) | 63.1% | Eikon Therapeutics, Inc. — SEC 8-K (2026-08-14), p.3 |
| Disease Control Rate (DCR) for EIK1001 (TeLuRide-005) | 90.8% | Eikon Therapeutics, Inc. — SEC 8-K (2026-08-14), p.3 |
| Objective Response Rate (ORR) in EIK1001 (TeLuRide-005) SQ cohort | 72.4% | Eikon Therapeutics, Inc. — SEC 8-K (2026-08-14), p.3 |
| Median Duration of Response (DOR) in EIK1001 (TeLuRide-005) NSQ cohort | > 11 months | Eikon Therapeutics, Inc. — SEC 8-K (2026-08-14), p.4 |
Key projects
- EIK1003 monotherapy (Prostate Cancer)
Objective Response Rate (ORR) (CR+PR) in Prostate Cancer was 100% for EIK1003 monotherapy (Cohort 1A).
- EIK1003 monotherapy (Pancreatic Cancer)
Objective Response Rate (ORR) (CR+PR) in Pancreatic Cancer was 0% for EIK1003 monotherapy (Cohort 1A).
- EIK1003 in combination with paclitaxel
Disease control rate (DCR: CR+PR+SD) was 79.2% for EIK1003 in combination with paclitaxel (Cohort 1C).
- EIK1001 (TeLuRide-005)
Objective Response Rate (ORR) (CR+PR) was 63.1% for EIK1001 (TeLuRide-005).
- TeLuRide-006
Trial initiation for TeLuRide-006 is Q2 2025.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →